Millennium Research Group's (MRG) Marketrack service reveals that the total market for cardiac rhythm management (CRM) including pacemakers and implantable cardioverter defibrillators (ICDs) grew 3.8% over the first two months of Q4 2006, compared to the first two months of Q3, with ICDs accounting for the vast majority of the growth.

Growth is primarily attributed to increasing confidence in ICDs, as marketing and communication efforts by industry players begin to pay off. Excitement is also beginning to generate over results from a new diagnostic test that was presented at the American Heart Association's annual conference in November. This new non-invasive test, created by Cambridge Heart, is intended to identify patients at risk of sudden cardiac death.

"The advent of this new test implies that more candidates will likely be referred for ICDs, increasing the potential patient population," says David Gardner, Senior Analyst at MRG.

Overall CRM market share data for Q4 to date (October and November) shows Medtronic in the lead at 53.5%, followed by St. Jude Medical at 23.6% and Boston Scientific at 22.9%.

November Marketrack data, released last week, highlights a slight decline month-over-month in Medtronic's CRT-D market share. St. Jude Medical's ICD share held relatively stable at 22%, while Boston Scientific, whose ICD share is recovering from the June recall, maintained a stable share in the pacemaker segment at nearly 18%.

About Cardiac Rhythm Management Marketrack

Cardiac Rhythm Management Marketrack™ gathers data from 150 electrophysiology labs throughout the US on a monthly basis. Marketrack subscribers receive thousands of data points, including usage (units, average selling price, and revenue), procedure, competitor, and brand information.

About Millennium Research Group

Millennium Research Group (http://www.mrg.net/), a Decision Resources, Inc. company (http://www.decisionresources.com/), is the global authority on medical technology market intelligence and a leading provider of strategic information to the health care sector. Focused solely on the medical device, pharmaceutical, and biotechnology industries, the company provides its clients with the benefits of its specialized industry expertise through published reports and customized consulting services.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Amy Krohn   Millennium Research Group   416-364-7776 x101   akrohn@mrg.net 

SOURCE: Millennium Research Group

CONTACT: Amy Krohn of Millennium Research Group, +1-416-364-7776 x101,
akrohn@mrg.net

Despite Higher Cost, Boehringer Ingelheim/Pfizer's Spiriva Consistently Leads Both Serevent and Foradil by a Wide Margin in First-, Second-, and Third-Line Therapy for the Treatment of Moderate COPD

View Now